Reposted by Andrew Rivas
A personalized mRNA cancer vaccine, added to an existing treatment, slowed the return of melanoma and its spread to other parts of the body in a late-stage clinical trial, the drugmakers Merck and Moderna announced Wednesday.
www.statnews.com/2026/08/19/m...
statnews.com
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.